Yu A Teliatnik

Research Institute - Regional Clinical Hospital No. 1 named after S.V. Ochapovsky, Krasnodar, Russia.

2 publications 2022 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does Yu A Teliatnik research?

Yu A Teliatnik studies how well a medication called Revelise, which contains alteplase, works for patients suffering from ischemic strokes. Ischemic stroke occurs when an artery supplying blood to the brain is blocked, and Revelise is used to help dissolve the clot. Teliatnik's research particularly examines the outcomes of patients, especially older individuals and those with additional health conditions, to ensure that they receive effective care when they need it most.

Key findings

  • In a study involving 2,202 patients, 49.9% had good outcomes upon discharge after treatment with Revelise.
  • After 90 days, the percentage of patients with good outcomes increased to 66.4%.
  • Revelise effectively reduces stroke-related disabilities, demonstrating significant benefits for older patients.

Frequently asked questions

Does Dr. Teliatnik study stroke treatments?
Yes, Dr. Teliatnik researches the treatment of ischemic stroke using the medication Revelise.
What are the outcomes of using Revelise for stroke patients?
In Dr. Teliatnik's studies, nearly half of the stroke patients treated with Revelise had good outcomes at discharge, rising to over 66% after three months.
Is Dr. Teliatnik's work relevant to older stroke patients?
Yes, Dr. Teliatnik specifically focuses on older patients and those with additional health issues to ensure they receive effective treatment.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].

2022

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Soldatov MA, Klimov LV, Tolmachev AP, Kiseleva TV, Androfagina OV +17 more

Plain English
This study looked at the use of a drug called Revelisa to treat people who had ischemic strokes, which happen when blood flow to the brain is blocked. Researchers treated 550 patients and found that about 45% showed significant improvement in their condition one day after treatment. Additionally, 68.5% of patients had good recovery by the time they were discharged from the hospital after 90 days. Who this helps: This research benefits patients experiencing ischemic strokes and their healthcare providers by showing that Revelisa can effectively reduce symptoms and improve recovery.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.